C12N 2770/24132
Use of virus as therapeutic agent, other than vaccine
Official title: Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
C12N2770/24132 (Use of virus as therapeutic agent, other than vaccine) appears on 21 US grants and 31 published applications in this corpus.
Search patents in C12N- Granted patents
- 21
- Published applications
- 31
- Assignees
- 23
- Inventors
- 46
- Latest grant
- 18 Nov 2025
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2000 | 1 | 0 |
| 2001 | 0 | 0 |
| 2002 | 0 | 0 |
| 2003 | 1 | 0 |
| 2004 | 0 | 0 |
| 2005 | 0 | 0 |
| 2006 | 0 | 0 |
| 2007 | 0 | 0 |
| 2008 | 0 | 1 |
| 2009 | 0 | 0 |
| 2010 | 0 | 0 |
| 2011 | 0 | 0 |
| 2012 | 0 | 0 |
| 2013 | 0 | 0 |
| 2014 | 0 | 0 |
| 2015 | 0 | 1 |
| 2016 | 0 | 0 |
| 2017 | 2 | 4 |
| 2018 | 1 | 1 |
| 2019 | 4 | 5 |
| 2020 | 3 | 6 |
| 2021 | 2 | 4 |
| 2022 | 0 | 2 |
| 2023 | 1 | 2 |
| 2024 | 2 | 3 |
| 2025 | 4 | 1 |
| 2026 | 0 | 1 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Zika virus constructs and therapeutic compositions thereof18 Nov 2025US 12,473,570 B2The Regents of the University of California
- Zika virus treatment of CD24-positive tumors and diseases associated with abnormal T cell activation and treating or preventing Zika virus infections12 Aug 2025US 12,383,588 B2The Nemours Foundation
- Compositions and methods for antigen targeting to CD18029 Jul 2025US 12,371,672 B2University of Washington
- Zika virus strains for treatment of glioma15 Apr 2025US 12,274,725 B2Board of Regents, The University of Texas System
- Method for treating cancer using dengue virus serotype 1 (DENV-1)13 Aug 2024US 12,059,443 B2Prime Vax Immuno-Oncology, Inc.
- Combination therapy of oncolytic virus drugs for cancer treatment26 Feb 2026US 2026/0053873 A1Sichuan Oncocare Biopharmaceutical, Inc.
- Oncolytic viruses and methods of use15 May 2025US 2025/0154509 A1Vyro Bio Inc.
- E protein-mutated west nile virus used as liveattenuated vaccine and oncolytic drug for cancer therapy17 Oct 2024US 2024/0342265 A1SICHUAN ANCOCARE BIOPHARMACEUTICAL, Ltd.
- Compositions and Methods for Antigen Targeting to CD18012 Sep 2024US 2024/0301364 A1University of Washington
- Pharmaceutical kit and uses thereof25 Jul 2024US 2024/0245738 A1Universidade de Sao Paulo-USP
Most cited
By later US patents
- Hyperthermia and immunotherapy for leukemias lymphomas, and solid tumors13US 6,524,587 B12003
- Hyperthermia and immunotherapy for cancer12US 6,048,686 ARandy Kyle Brown · 2000
- Compositions and methods for combination therapy with dengue virus and dendritic cells8US 9,730,989 B2Primevax Immuno-Oncology, Inc. · 2017
- Compositions and methods for combination therapy with dengue virus and dendritic cells8US 9,849,167 B2Primevax Immuno-Oncology, Inc. · 2017
- Compositions and methods for antigen targeting to CD1806US 10,196,614 B2University of Washington through its Center for Commercialization · 2019